Myelopathy

Children's Wisconsin, Froedtert & the Medical College of Wisconsin, the Medical College of Wisconsin and Zablocki VA Medical Center Launch Wisconsin Institute of NeuroScience

Retrieved on: 
Wednesday, February 7, 2024
Partnership, Myelopathy, Clement, Concussion, Neuroscience, School, WINS, Research, Patient, Medical college, Peripheral nervous system, Physician, Brain, Spine, MCW, DCM, Doctor of Philosophy, Rehabilitation, Spinal cord

MILWAUKEE, Feb. 7, 2024 /PRNewswire/ -- Milwaukee is now home to one of the nation's first institutes designed specifically to focus on the neurological needs of people from birth to old age. The Wisconsin Institute of NeuroScience (WINS) is a partnership of Children's Wisconsin, the Froedtert & the Medical College of Wisconsin health network, the Medical College of Wisconsin (MCW) and the Clement J. Zablocki Veterans' Administration Medical Center.

Key Points: 
  • The Wisconsin Institute of NeuroScience (WINS) is a partnership of Children's Wisconsin, the Froedtert & the Medical College of Wisconsin health network, the Medical College of Wisconsin (MCW) and the Clement J. Zablocki Veterans' Administration Medical Center.
  • "Importantly, WINS also will further the groundbreaking research already underway here and increase educational opportunities so we can produce the next generation of neuroscientists."
  • Despite being one of the most common causes of spinal cord injury, public awareness of DCM remains limited.
  • The Center for Cervical Myelopathy aims to fill that void by providing patients, physicians and scientists with resources to advance understanding and treatment of this condition.

Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 January 2024

Retrieved on: 
Sunday, February 4, 2024
Civil service commission, Pneumonia, Febrile neutropenia, Eli Lilly, Triprolidine, International, Bacteria, Schizophrenia, Myelopathy, Incidence, ALD, Cefepime, Allergic rhinitis, Nasal congestion, Neutrophil, Agency, COMP, Fever, HAP, EEIG, Headache, Static pressure, Medicine, Committee, Conditional, Spinal cord, Hospital-acquired pneumonia, PTC, Neutropenia, Public, CHMP, European, AMD, Patient, Diagnosis, Marketing, RCVS, European Commission, Brain, Disease, Infection, Inflammation, Male, PRES, PRAC, Pain, Pyelonephritis, Urinary tract infection, VAP, Ageing, EMA, Geographic atrophy, Adrenoleukodystrophy, Therapy, News, INN, Duchenne muscular dystrophy, Common, Fungal infection, Vaccine

Three new medicines recommended for approvalEMA’s human medicines committee (CHMP) recommended three medicines for approval at its January 2024 meeting.The committee recommended…, Positive recommendations on new medicines, Exblifep International non-proprietary name (INN)cefepime / enmetazobactam Marketing-authorisation applicantAdvanz Pharma LimitedTherapeutic indicationTreatment of: 1)…, Ryzneuta INNefbemalenograstim alfaMarketing-authorisation applicantEvive Biotechnology Ireland LimitedTherapeutic indicationReduction in the duration of neutropenia and…, Positive recommendations on new generic medicines, Niapelf INNpaliperidoneMarketing-authorisation applicantNeuraxpharm Pharmaceuticals S.L.Therapeutic indicationTreatment of schizophreniaMore informationNiapelf: Pending…, Negative recommendations on new medicines, Nezglyal INNleriglitazoneMarketing-authorisation applicantMinoryx Therapeutics S.L.Therapeutic indicationTreatment of cerebral progression and myelopathy in male…, Syfovre INNpegcetacoplanMarketing-authorisation applicantApellis Netherlands B.V.Therapeutic indicationTreatment of geographic atrophy (GA) secondary to age-related…, Positive recommendations on extensions of indications, Abecma INNidecabtagene vicleucel Marketing-authorisation holderBristol-Myers Squibb Pharma EEIGMore informationAbecma: Pending EC decision, Prevenar 20 (previously Apexxnar) Common namepneumococcal polysaccharide conjugate vaccine (20-valent, adsorbed)Marketing-authorisation holderPfizer Europe MA EEIGMore…, Aspaveli INNpegcetacoplanMarketing-authorisation holderSwedish Orphan Biovitrum AB (publ)More informationAspaveli: Pending EC decision, Retsevmo INNselpercatinibMarketing-authorisation holderEli Lilly Nederland B.V.More informationRetsevmo: Pending EC decision, Outcome of re-examination of recommendation on non-renewal of Conditional Marketing Authorisation, Translarna INNataluren Marketing-authorisation holderPTC Therapeutics International LimitedNewsEMA confirms recommendation for non-renewal of authorisation of Duchenne…, Outcome of referral, Pseudoephedrine Marketing-authorisation holderVarious companiesMore informationPseudoephedrine-containing medicinal products, Re-examination of conclusion of referral, Synapse Labs Pvt.

Key Points: 
  • Three new medicines recommended for approvalEMA’s human medicines committee (CHMP) recommended three medicines for approval at its January 2024 meeting.The committee recommended…, Positive recommendations on new medicines, Exblifep International non-proprietary name (INN)cefepime / enmetazobactam Marketing-authorisation applicantAdvanz Pharma LimitedTherapeutic indicationTreatment of: 1)…, Ryzneuta INNefbemalenograstim alfaMarketing-authorisation applicantEvive Biotechnology Ireland LimitedTherapeutic indicationReduction in the duration of neutropenia and…, Positive recommendations on new generic medicines, Niapelf INNpaliperidoneMarketing-authorisation applicantNeuraxpharm Pharmaceuticals S.L.Therapeutic indicationTreatment of schizophreniaMore informationNiapelf: Pending…, Negative recommendations on new medicines, Nezglyal INNleriglitazoneMarketing-authorisation applicantMinoryx Therapeutics S.L.Therapeutic indicationTreatment of cerebral progression and myelopathy in male…, Syfovre INNpegcetacoplanMarketing-authorisation applicantApellis Netherlands B.V.Therapeutic indicationTreatment of geographic atrophy (GA) secondary to age-related…, Positive recommendations on extensions of indications, Abecma INNidecabtagene vicleucel Marketing-authorisation holderBristol-Myers Squibb Pharma EEIGMore informationAbecma: Pending EC decision, Prevenar 20 (previously Apexxnar) Common namepneumococcal polysaccharide conjugate vaccine (20-valent, adsorbed)Marketing-authorisation holderPfizer Europe MA EEIGMore…, Aspaveli INNpegcetacoplanMarketing-authorisation holderSwedish Orphan Biovitrum AB (publ)More informationAspaveli: Pending EC decision, Retsevmo INNselpercatinibMarketing-authorisation holderEli Lilly Nederland B.V.More informationRetsevmo: Pending EC decision, Outcome of re-examination of recommendation on non-renewal of Conditional Marketing Authorisation, Translarna INNataluren Marketing-authorisation holderPTC Therapeutics International LimitedNewsEMA confirms recommendation for non-renewal of authorisation of Duchenne…, Outcome of referral, Pseudoephedrine Marketing-authorisation holderVarious companiesMore informationPseudoephedrine-containing medicinal products, Re-examination of conclusion of referral, Synapse Labs Pvt.
  • Ltd. Marketing-authorisation holderVarious companiesMore informationSynapse

The Inner Circle Acknowledges, Harshpal Singh, MD, FAANS as a Distinguished Healthcare Professional for his contributions to the Neurological Field

Retrieved on: 
Wednesday, September 27, 2023
Spinal fusion, Icahn School of Medicine at Mount Sinai, University, Education, Tetraplegia, Neurosurgery, Laminectomy, Medical college, Neurology, Corpectomy, Medical College of Georgia, Deformity, Multimedia, Inner circle, Congress, American Board of Commissioners for Foreign Missions, Subarachnoid hemorrhage, Congress of Neurological Surgeons, American Association of Neurological Surgeons, MD, Patient, Mount Sinai School, Nerve, Myelopathy, Sport, Textbook, Neuro, Medical degree, Veterinary medicine, Dentistry, Spine, Augmented fifth, Medicine

ENGLEWOOD CLIFFS, N.J., Sept. 27, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Harshpal Singh, MD, FAANS is acknowledged as a Distinguished Healthcare Professional for his contributions to the Neurological Field.

Key Points: 
  • ENGLEWOOD CLIFFS, N.J., Sept. 27, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Harshpal Singh, MD, FAANS is acknowledged as a Distinguished Healthcare Professional for his contributions to the Neurological Field.
  • He completed a residency at Mount Sinai School of Medicine where he served as Chief Resident.
  • The doctor is also a specialist in spinal fusion; corpectomy; vertebroplasty; kyphoplasty; laminectomy; and difficult revision spinal surgery.
  • Aside from his professional pursuits, the doctor enjoys funding programs that distribute sports equipment to the disadvantaged in Punjab, India.

Locate Bio’s LDGraft Granted FDA Breakthrough Device Designation

Retrieved on: 
Thursday, May 18, 2023
Medical Devices, FDA, Health, Surgery, Pharmaceutical, Biotechnology, Spinal fusion, Surgeon, Low back pain, Bio, Degenerative disc disease, Disability, Myelopathy, Quality of life, Bone morphogenetic protein 2, Spinal disc herniation, Radiculopathy, Patient, DDD, Diagnosis, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Spinal stenosis, Pharmaceutical industry, Locate

Locate Bio, a UK-based orthobiologics company, is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device designation for LDGraft, currently in development for anterior lumbar interbody spinal fusion (ALIF) procedures at one level from L3-S1 for patients with degenerative disc disease.

Key Points: 
  • Locate Bio, a UK-based orthobiologics company, is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device designation for LDGraft, currently in development for anterior lumbar interbody spinal fusion (ALIF) procedures at one level from L3-S1 for patients with degenerative disc disease.
  • The FDA Breakthrough Device Program is designed to accelerate patient access to promising technologies that have the potential to provide more effective treatment or diagnosis for life-threatening or irreversibly debilitating diseases or conditions.
  • We are delighted therefore to have been granted a Breakthrough Device designation from the FDA for LDGraft, our exciting controlled and extended-release rhBMP-2 for spinal fusion.
  • We are proud that the FDA has recognised the potential of LDGraft.

The Inner Circle Acknowledges, Harshpal Singh, MD, FAANS as a Most Trusted Healthcare Professional for his contributions to the Neurological Field.

Retrieved on: 
Wednesday, May 17, 2023
Spinal fusion, Tetraplegia, Icahn School of Medicine at Mount Sinai, University, Neurosurgery, Laminectomy, Medical college, Neurology, Corpectomy, Medical College of Georgia, Deformity, Multimedia, Inner circle, Congress, American Board of Commissioners for Foreign Missions, Subspecies (film series), Subarachnoid hemorrhage, American Association of Neurological Surgeons, MD, Patient, Congress of Neurological Surgeons, Mount Sinai School, Nerve, Myelopathy, Sport, Textbook, Neuro, Dentistry, Spine, Augmented fifth, Medicine

ENGLEWOOD CLIFFS, N.J., May 17, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Harshpal Singh, MD, FAANS is acknowledged as a Most Trusted Healthcare Professional for his contributions to the Neurological Field.

Key Points: 
  • ENGLEWOOD CLIFFS, N.J., May 17, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Harshpal Singh, MD, FAANS is acknowledged as a Most Trusted Healthcare Professional for his contributions to the Neurological Field.
  • He completed a fellowship training at the University of Miami where he focused on treating spinal cord injuries severe spinal trauma and complex cervical spine deformities.
  • He is a board-certified neurosurgeon who has advanced subspecialized training in both neuro-radiology and complex and minimally invasive spinal surgery.
  • He notes that he has extensive experience treating a broad range of complex patient conditions using the latest treatment approaches.

Dr Kingsley R Chin Warns Against Expert Surgeon Witnesses Supporting Copycat Pedicle Screw Lawsuits

Retrieved on: 
Friday, December 23, 2022
Surgeon, Neurosurgery, Sympathy, Paralysis, Patient, Weakness, Elective surgery, Myelopathy, Health, University, Lawyer, CT, Spinal cord, Risk, Nerve injury, Pseudomeningocele, Hypoesthesia, Death, S1, Spine, Pain, MBA, Human, Sale, Research, Vertebral artery, Malpractice, Record, Dentistry, Injection moulding

MALDEN, Mass., Dec. 23, 2022 /PRNewswire-PRWeb/ -- Neurosurgeons and orthopedic spine surgeons perform surgeries around the spinal cord and nerves, which are highly delicate structures. Often patients present with disabling pain, numbness, weakness, and, in severe cases, paralysis and loss of bowel and bladder functions. Many patients are willing to brave the risks of a surgery over living with their disabling spine conditions. Patients tend to know the risks of spine surgery from online research or speaking to other patients who had spine surgery. The spine surgeon and staff then sit down with the patient and further explain the risks before the patient signs a legal consent document, without which the surgeon cannot perform the surgery. The risks include loosening or breakage of screws or other hardware, nerve injuries, spinal cord injury, weakness, numbness, paralysis, and even death.

Key Points: 
  • DoctorpreneurNews.com sat down with board-certified professor of orthopedic spine surgery Dr. Kingsley R Chin to discuss the topic of the specter of expert spine surgeon witnesses required in copycat pedicle screw lawsuits to succeed in court.
  • These expert surgeons are paid on average over $500 per hour, travel expenses on average of $10,000 per day to appear in court" said Dr. Chin.
  • Over 3,000 pedicle screw lawsuits were filed in the 90's against surgeons who performed pedicle screw surgeries and spine societies whose educational programs supported pedicle screws .
  • I was an expert witness for a neurosurgeon sued due to placing long pedicle screws at S1 on both sides.

Synergy Spine Solutions and Ortho Consulting Group extend strategic partnership to commercialize innovative spine technologies

Retrieved on: 
Monday, September 12, 2022
Vision, IDE, Growth, Synergy, Partnership, Patient, Thought, DDD, Marquess, Technology, SME, Quality of life, Standard of care, Spine, EMEA, Leadership, Solution, OCG, Surgeon, Motion, Marketing, Education, Radiculopathy, Myelopathy, Fine chemical, Renewable energy

NEWBURY, England, Sept. 12, 2022 /PRNewswire/ -- Orthopaedic medical devices developer Synergy Spine Solutions (Synergy) has announced it is extending its strategic partnership with international growth specialists Ortho Consulting Group (OCG) to lead their expansion across the EMEA region.

Key Points: 
  • NEWBURY, England, Sept. 12, 2022 /PRNewswire/ -- Orthopaedic medical devices developer Synergy Spine Solutions(Synergy)has announced it is extending its strategic partnership with international growth specialists Ortho Consulting Group (OCG) to lead their expansion across the EMEA region.
  • The Vision of Synergy Spine Solutions is to identify and commercialize innovative spine technologies that help surgeons improve their patients' quality of life and advance the standard of care.
  • In the United States,the Synergy Disc is investigational use only andSynergy is currently enrolling patients in its IDE study.
  • For more information, visit synergyspinesolutions.com
    Ortho Consulting Group helps companies within the orthopaedic and spine industry build and strengthen their global sales channels.

Synergy Spine Solutions and Ortho Consulting Group extend strategic partnership to commercialize innovative spine technologies

Retrieved on: 
Monday, September 12, 2022
Vision, IDE, Growth, Synergy, Partnership, Patient, Thought, DDD, Marquess, Technology, SME, Quality of life, Standard of care, Spine, EMEA, Leadership, Solution, OCG, Surgeon, Motion, Marketing, Education, Radiculopathy, Myelopathy, Fine chemical, Renewable energy

NEWBURY, England, Sept. 12, 2022 /PRNewswire/ -- Orthopaedic medical devices developer Synergy Spine Solutions (Synergy) has announced it is extending its strategic partnership with international growth specialists Ortho Consulting Group (OCG) to lead their expansion across the EMEA region.

Key Points: 
  • NEWBURY, England, Sept. 12, 2022 /PRNewswire/ -- Orthopaedic medical devices developer Synergy Spine Solutions(Synergy)has announced it is extending its strategic partnership with international growth specialists Ortho Consulting Group (OCG) to lead their expansion across the EMEA region.
  • The Vision of Synergy Spine Solutions is to identify and commercialize innovative spine technologies that help surgeons improve their patients' quality of life and advance the standard of care.
  • In the United States,the Synergy Disc is investigational use only andSynergy is currently enrolling patients in its IDE study.
  • For more information, visit synergyspinesolutions.com
    Ortho Consulting Group helps companies within the orthopaedic and spine industry build and strengthen their global sales channels.

SwanBio Presents Design of Innovative Natural History Study Aimed to Evolve Understanding of Adrenomyeloneuropathy and Inform Future Treatments

Retrieved on: 
Monday, June 27, 2022
Science, Other Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Genetics, FDA, Patient, Hereditary spastic paraplegia, Falls, AMN, ABCD1, Research, Tissue, HIV disease progression rates, Trial of the century, Incontinence, Man, AAV, Disease, Quality of life, Pain, Endpoint security, European Academy of Neurology, Mass, Sexual dysfunction, Clinical trial, Learning, Congress, Drug development, EAN, Primate, Safety, Intention, Mutation, Therapy, Pharmaceutical industry, Medical imaging, Medical device, Adrenoleukodystrophy, Myelopathy

CYGNET is the first AMN clinical study to feature wearables, which may help us identify sensitive outcomes related to clinically relevant changes early in men with AMN.

Key Points: 
  • CYGNET is the first AMN clinical study to feature wearables, which may help us identify sensitive outcomes related to clinically relevant changes early in men with AMN.
  • SwanBio anticipates recruiting approximately 80 patients for the CYGNET natural history study; as of early June, the study was over 40% enrolled across five different global sites.
  • Clinicians or patients interested in learning more about this study can review SwanBios CYGNET flyer or contact SwanBio at [email protected] .
  • SwanBio Therapeutics is a gene therapy company that aims to bring life-changing treatments to people with devastating, inherited neurological conditions.

New Publication Supports Clinical Effectiveness of Centinel Spine's STALIF® Integrated Interbody™ System

Retrieved on: 
Tuesday, October 26, 2021
Research, Myelopathy, Patient, LLC, Trial of the century, Journal, Treatment, Radiculopathy, Safety, Birth control

"1 The prospective multi-center study supports that patients receiving STALIF C-Ti implants demonstrated significant improvements in clinical outcome scores with minimal overall complication rate.

Key Points: 
  • "1 The prospective multi-center study supports that patients receiving STALIF C-Ti implants demonstrated significant improvements in clinical outcome scores with minimal overall complication rate.
  • This study was undertaken to determine if there was an advantage to an Integrated Interbody device over traditional plated fusion.
  • We are dedicated to advancing evidence that further supports the stand-alone fusion platform that was pioneered by Centinel Spine."
  • Centinel Spine remains the only company with comprehensive motion-preserving and fusion solutions for both cervical and lumbar anterior column reconstruction.